Sorry, you need to enable JavaScript to visit this website.

ALDACTONE (Spironolactone Tablets, USP)

Health Professional Information

SUMMARY PRODUCT INFORMATION

Route of Administration

Dosage Form / Strength

Nonmedicinal Ingredients

oral

tablet 25 mg, 100 mg

Calcium sulfate, corn starch, magnesium stearate, peppermint flavouring, povidone, hypromellose, polyethylene glycol 400, carnauba wax, stearic acid, Opaspray M-1-2042 (25 mg), Opaspray M-1-2668

(100 mg).

Indications And Clinical Use

ALDACTONE (spironolactone) is indicated for the following:

  1. Primary Hyperaldosteronism

    ALDACTONE (spironolactone) is a useful agent in the diagnosis of primary hyperaldosteronism. In the presence of hypokalemic alkalosis and hypertension, a diagnosis of primary hyperaldosteronism should be considered if both blood pressure (BP) and serum electrolytes return to normal following treatment with ALDACTONE.

  2. ALDACTONE is useful in the pre‑operative treatment of patients with primary hyperaldosteronism and for the maintenance therapy of such patients who decline surgery, or who are unsuitable for surgery.

  3. Edematous Conditions

  4. a) Congestive Heart Failure (CHF):
    ALDACTONE is useful in the management of edema and sodium retention in CHF when the patient is only partially responsive to, or intolerant of, other therapeutic measures. ALDACTONE may be used alone or with thiazides. It is indicated in patients with CHF taking digitalis when other therapies are considered inappropriate.

    b) Cirrhosis of the Liver Accompanied by Edema and/or Ascites:
    Aldosterone levels may be exceptionally high in this condition. ALDACTONE is indicated for maintenance therapy, in combination with bed rest and the restriction of fluid and sodium.

    c) The Nephrotic Syndrome:
    ALDACTONE is useful for inducing a diuresis in patients not responsive to glucocorticoid therapy (for the nephrotic syndrome), and not responding to other diuretics. However, ALDACTONE has not been shown to affect the basic pathological process.

  5. Essential Hypertension
    ALDACTONE is indicated, usually in combination with other drugs, for patients who cannot be treated adequately with other agents or for whom other agents are considered inappropriate. ALDACTONE alone has mild to moderate antihypertensive activity.

  6. Hypokalemia
    ALDACTONE is indicated for treatment of hypokalemia, when other measures are considered inappropriate or inadequate. It is also indicated for the prophylaxis of hypokalemia in digitalis therapy when other measures are inadequate or inappropriate.

Contraindications

ALDACTONE is contraindicated in:

  • Patients who are hypersensitive to spironolactone, or to any ingredient in the formulation.
  • For a complete listing, see the Dosage Forms, Composition and Packaging Section.
  • Patients with anuria
  • Patients with Addison’s disease
  • Patients with acute renal insufficiency or with severe impairment of renal function (GFR < 30 mL/Min/1.73 m2
  • Patients with hyperkalemia
  • Women who are pregnant
  • Nursing women (see WARNINGS AND PRECAUTIONS, Special Populations, Nursing Women)
  • Combination with eplerenone ( see Warnings and Precautions- Hyperkalemia, Drug Interactions sections)

  • Combination with heparin, low molecular weight heparin ( see Warnings and Precautions- Hyperkalemia, Drug Interactions sections)

Warnings And Precautions

Avoid potassium supplements, salt substitutes and foods containing high levels of potassium (e.g., bananas, prunes, raisins and orange juice).

Follow your doctor's directions for a low-salt or low-sodium diet and daily exercise program.

General

Use only for "Indications": Use ALDACTONE (spironolactone) only for conditions described under "INDICATIONS".

Potassium (K+) Supplementation: The concurrent administration of potassium supplements, a diet rich in potassium, or other K+-sparing diuretics is not recommended as this may induce hyperkalemia.

Somnolence and dizziness: Somnolence and dizziness have been reported to occur in some patients. Caution is advised when driving or operating machinery until the response to initial treatment has been determined.

Carcinogenesis and Mutagenesis

Tumorigenicity: Spironolactone, in chronic toxicity studies, has been shown to be a tumorigen in rats. Breast cancer and other neoplasms (intestinal, pancreas, etc) have been reported in postmarket surveillance.

Endocrine and Metabolism

Gynecomastia: Gynecomastia may develop with the use of ALDACTONE and physicians should be advised of its possible occurrence. The development of gynecomastia appears to be related to both dosage and duration of therapy and is normally reversible when the drug is discontinued. If gynecomastia develops, discontinue the drug. In rare instances some breast enlargement may persist.

Hyperchloremic metabolic acidosis: Reversible hyperchloremic metabolic acidosis, usually in association with hyperkalemia, has been reported to occur in some patients with decompensated hepatic cirrhosis, even when renal function is normal. Caution should be used in treating patients with acute or severe liver impairments, since vigorous diuretic therapy may precipitate hepatic encephalopathy.

Acidosis and Renal Function: Rare reports of acidosis have been reported with ALDACTONE.

Hematologic

Electrolyte Balance: Because of the diuretic action of ALDACTONE patients should be carefully evaluated for possible disturbance of fluid and electrolyte balance, due to the possibility of hyperkalemia, hypochloremic alkalosis, hyponatremia and possible blood urea nitrogen (BUN)elevation, especially the elderly and/or patients with pre-existing impaired renal or hepatic function.

a) Hyperkalemia

Hyperkalemia may occur in patients treated with ALDACTONE if the potassium intake is excessive. This can cause cardiac irregularities, some of which may be fatal. Hyperkalemia may also occur even in the absence of potassium supplementation, particularly in patients with impaired renal function, elderly patients, or patients with diabetes. Consequently, no potassium supplementation should ordinarily be given with ALDACTONE. ALDACTONE should not be administered concurrently with other potassium-sparing diuretics. ALDACTONE, when used with angiotensin converting enzyme (ACE) inhibitors, nonsteroidal anti-inflammatory drugs, Angiotensin II antagonists, other aldosterone blockers, even in the presence of a diuretic, has been associated with severe hyperkalemia (See Drug Interactions section).
Concomitant use of spironolactone with heparin, low molecular weight heparin, or other drugs or conditions known to cause hyperkalemia, may lead to severe hyperkalemia (See Contraindications, Drug Interactions section).

Hyperkalemia in Patients with Moderate to Severe Heart Failure

As hyperkalemia may be fatal, it is critical to monitor and manage serum potassium in patients with heart failure receiving ALDACTONE. Avoid using other potassium-sparing diuretics. Avoid using oral potassium supplements in patients with serum potassium > 3.5 mEq/L. No information is available regarding patients with serum creatinine > 2.5 mg/dL or a recent increase in serum creatinine >25%. The recommended monitoring for potassium and creatinine is one week after initiation or increase in dose of ALDACTONE, monthly for the first 3 months, then quarterly for a year, and then every 6 months. Discontinue or interrupt treatment for serum potassium > 5 mEq/L or for serum creatinine > 4 mg/dL.

Hyperkalemia in Patients with Diabetes
Diabetic patients who are treated with ALDACTONE should also be treated with caution as they have an increased risk of hyperkalemia. The status of the patient’s renal function and serum potassium levels should be assessed prior to initiating treatment and repeated within a few days and a few weeks thereafter in the patient at risk, especially in elderly patients. The recommended monitoring for potassium and creatinine is one week after initiation or increase in dose of spironolactone, monthly for the first 3 months, then quarterly for a year, and then every 6 months.
Hyperkalemia can be treated promptly by rapid intravenous administration of glucose (20 to 50%) and regular insulin, using 0.25 to 0.5 units of insulin per gram of glucose. This is a temporary measure to be repeated if required. ALDACTONE should be discontinued and potassium intake (including dietary potassium) restricted.

b) Hyponatremia
During the administration of ALDACTONE patients suffering from sodium depletion must be attentively monitored and signs of electrolyte imbalance must be carefully checked.

ALDACTONE may, if administered concomitantly with other diuretics, cause or aggravate hyponatremia, as manifested by dryness of the mouth, thirst, lethargy, and drowsiness.

Hepatic/Biliary/Pancreatic

Impaired Hepatic Function: ALDACTONE should be used with caution in patients with impaired hepatic function because minor alterations of fluid and electrolyte balance may precipitate hepatic coma.

Management of Cirrhosis: Although high doses of ALDACTONE are required to treat edema and ascites in patients with cirrhosis, the drug dosage may be decreased before diuresis is complete to avoid the possibility of dehydration.

Neurologic: Lithium generally should not be given with diuretics (See DRUG INTERACTIONS).

Sexual Function/Reproduction

In a reproduction study in which female rats received dietary doses of 15 and 50 mg/kg/day spironolactone, there were no effects on mating or fertility, but there was a small increase in incidence of stillborn pups at the higher dose. When injected into female rats (100 mg/kg/day, 7 days i.p.) spironolactone was found to increase the length of the estrous cycle by prolonging diestrus during treatment and inducing constant diestrus during a two-week, post-treatment observation period. These effects were associated with retarded ovarian follicle development and a reduction in circulating estrogen levels, which would be expected to impair mating, fertility and fecundity. Spironolactone (100 mg/kg/day i.p.) administered to female mice decreased the number of mated mice that conceived, and decreased the number of implanted embryos in those that became pregnant; at 200 mg/kg/day it also increased the latency period to mating.

Special Populations

Pregnant Women: Spironolactone and its metabolites do cross the placental barrier. There are no studies in pregnant women. Therefore, the use of ALDACTONE requires that the potential benefits be weighed against the possible hazard to the mother and fetus.

Spironolactone was devoid of teratogenic effects in mice. Rabbits receiving spironolactone showed reduced conception rate, increased resorption rate, and lower number of live births. No embryotoxic effects were seen in rats administered high dosages, but limited, dose-related hypoprolactinemia and decreased ventral prostate and seminal vesicle weights in males, and increased leutinizing hormone secretion and ovarian and uterine weights in females were reported. Feminization of the external genitalia of male fetuses was reported in another rat study.

Nursing Women: see CONTRAINDICATIONS

Canrenone, a major (and active) metabolite of spironolactone, appears in human breast milk. Because of the unknown potential for adverse events on the breast-feeding infant, a decision should be made whether to discontinue breast-feeding or discontinue the drug, taking into account the importance of the drug to the mother.

Monitoring and Laboratory Tests

General: ALDACTONE therapy may cause transient elevation of BUN, especially in patients with pre‑existing renal impairment.

Several reports of possible interference with digoxin radioimmunoassays by spironolactone or its metabolites have appeared in the literature. Neither the extent nor the potential clinical significance of this interference (which may be assay‑specific) has been fully established.

Discontinue spironolactone for at least 4, and preferably 7, days prior to plasma cortisol determinations, if they are to be done by the method of Mattingly, that is, by fluorometric assay. No interference has been demonstrated with the competitive protein binding technique or radioimmunoassay technique.

Adrenal Vein Catheterization and Plasma Renin Activity: Discontinue spironolactone several days prior to adrenal vein catheterization for measurement of aldosterone concentrations and measurements of plasma renin activity.

Adverse Reactions

The following adverse reactions have been reported in association with ALDACTONE (spironolactone):

Blood and lymphatic system disorders: Leukopenia (including agranulocytosis), thrombocytopenia, anemia.

Gastrointestinal disorders: Diarrhea and cramping, gastric bleeding, gastritis, nausea, ulceration, vomiting.

General disorders and administration site conditions: Malaise. ATAXIA

Hepatobiliary disorders: Abnormal hepatic function. A few cases of mixed cholestatic/hepatocellular toxicity, with one reported fatality, have been reported with spironolactone administration.

Immune system disorders: Drug fever, urticaria, maculopapular or erythematous cutaneous eruptions, anaphylactic reactions, vasculitis, pruritus, rash.

Metabolism and nutrition disorders: Electrolyte disturbances, hyperkalemia.

Musculoskeletal and connective tissue disorders: Leg cramps, muscle spasms, rhabdomyolysis, myalgia, weakness

Nervous system/psychiatric disorders: Mental confusion, ataxia, headache, drowsiness, lethargy, dizziness, change in libido.

Renal and urinary disorders: Renal dysfunction (including acute renal failure).

Reproductive system and breast disorders: gynecomastia* (see WARNINGS and PRECAUTIONS-Carcinogenesis and Mutagenesis), erectile dysfunction (inability to achieve or maintain erection), abnormal semen (decreased motility and sperm count), irregular menses or amenorrhea, postmenopausal bleeding, benign breast neoplasm, breast pain, breast carcinoma (including male patients)

Respiratory, thoracic and mediastinal disorders: Dysphonia, dyspnea.

Skin and subcutaneous tissue disorders: Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), drug rash with eosinophilia and systemic symptoms (DRESS), alopecia, hypertrichosis.

*Gynecomastia may develop with the use of spironolactone, and physicians should be advised of its possible occurrence. Development of gynecomastia is related to both dose and duration of therapy. If gynecomastia develops, discontinue the drug. Gynecomastia is usually reversible when spironolactone is discontinued, although in rare instances some breast enlargement may persist.

Adverse reactions are usually reversible upon discontinuation of the drug.

Drug Interactions

Drug-Drug Interactions

Table 1. Established or Potential Drug-Drug Interactions

Aldactone Drug Interaction

Effect

Clinical comment

Alcohol, barbiturates or narcotics

Potentiation of orthostatic hypotension may occur.

Avoid alcohol, barbiturates or narcotics, especially with initiation of therapy.

Antipyrine

Spironolactone enhances the metabolism of antipyrine.

Cholestyramine/ Ammonium Chloride

Hyperchloremic metabolic acidosis, frequently associated with hyperkalemia, has been reported in patients given spironolactone concurrently with ammonium chloride or cholestyramine.

Corticosteroids, and adrenocorticotropic hormone (ACTH)

Intensified electrolyte depletion, particularly hypokalemia, may occur.

Monitor serum potassium, and adjust medications, as required.

Diuretics and Antihypertensives

Although ALDACTONE may be administered concomitantly with diuretics and antihypertensives, the effect of ALDACTONE is additive.

Hyperkalemia has been associated with the use of angiotensin converting enzyme (ACE) inhibitors, nonsteroidal anti-inflammatory drugs, angiotensin II antagonists and aldosterone blockers in combination with spironolactone.

It is advisable to reduce the dose of these drugs. In particular, the dose of ganglionic blocking agents should be reduced by at least 50% when ALDACTONE is added to the regimen.

Eplerenone

Severe hyperkalemia has been associated with the use of aldosterone blockers in combination with spironolactone.

Heparin, low molecular weight heparin

Concomitant use of spironolactone with heparin, low molecular weight heparin may lead to severe hyperkalemia.

Drugs known to cause hyperkalemia

Concomitant use of drugs known to cause hyperkalemia with spironolactone may result in severe hyperkalemia

Lithium

Diuretic agents reduce the renal clearance of lithium and add a high risk of lithium toxicity.

Lithium generally should not be given with diuretics.

Norepinephrine

ALDACTONE reduces the vascular responsiveness to norepinephrine.

Caution should be exercised in the management of patients subjected to regional or general anaesthesia while being treated with spironolactone.

Digoxin

Spironolactone has been shown to increase the half‑life of digoxin. This may result in increased serum digoxin levels and subsequent digitalis toxicity.

It may be necessary to reduce the maintenance dose of digoxin when spironolactone is administered, and the patient should be carefully monitored to avoid over‑ or underdigitalization.

Non‑Steroidal Anti‑Inflammatory Drugs

Nonsteroidal anti-inflammatory drugs such as ASA, mefenamic acid, and indomethacin may attenuate the natriuretic efficacy of diuretics due to inhibition of intrarenal synthesis of prostaglandins and have been shown to attenuate the diuretic action of spironolactone.

Hyperkalemia has been associated with the use of indomethacin in combination with potassium‑sparing diuretics.

However, it has been shown that ASA does not alter the effect of spironolactone on blood pressure, serum electrolytes, urea nitrogen, or plasma renin activity in hypertensive patients.

If combination use is necessary, monitor renal function, serum potassium, and blood pressure closely. Dose adjustment may be required.

Drug-Food Interactions

In a 9 subject study, statistically significant increases of approximately 2-fold in spironolactone AUC(0-24) and greater than 2-fold in Cmax were reported after food co-administration.  At the same time, increases of approximately 1.4-fold were seen in Cmax and AUC(0-24) of canrenone.

The clinical importance of this finding is not known.

Drug-Laboratory Test Interactions

Several reports of possible interference with digoxin radioimmunoassays by spironolactone, or its metabolites, have appeared in the literature. Neither the extent, nor the potential clinical significance of its interference (which may be assay specific) has been fully established.

Spironolactone has been shown to increase the half‑life of digoxin. This may result in increased serum digoxin levels and subsequent digitalis toxicity (see Drug-Drug Interactions).

Dosage And Administration

  1. Diagnosis and Treatment of Primary Hyperaldosteronism

    As an initial diagnostic measure to provide presumptive evidence of primary hyperaldosteronism while patients are on normal diets:

    Long Test: Administer ALDACTONE at a daily dosage of 400 mg for 3-4 weeks. Correction of hypokalemia and hypertension provides presumptive evidence for the diagnosis of primary hyperaldosteronism.

    Short Test: Administer ALDACTONE at a daily dosage of 400 mg x 4 days. If serum potassium increases or urinary potassium decreases during ALDACTONE administration, but reverts when ALDACTONE is discontinued, a presumptive diagnosis of primary hyperaldosteronism should be considered.

    After the diagnosis of primary hyperaldosteronism has been established by more definitive testing procedures, ALDACTONE may be administered in doses of 75 mg to 400 mg daily in preparation for surgery. For those unsuitable for surgery, spironolactone may be employed for long term maintenance therapy at the lowest effective dosage determined for the individual.

  2. Edematous Disorders Associated with Congestive Heart Failure, Cirrhosis and the Nephrotic Syndrome

    When given as sole agent for diuresis, continue administration for at least 5 days. If an adequate response has been achieved within 5 days, continue dosage at the same level (or in selected patients, at a reduced dosage) in either single or divided daily doses. Some may respond adequately to a dosage of only 75 mg daily. If adequate diuresis is not obtained within 5 days, a second diuretic also should be given for additive effect. Occasionally for severe resistant edema, one may add a potent glucocorticoid to this combined therapy. Normally, an initial daily dosage of 100 mg (but may range from 25 mg to 200 mg daily) of ALDACTONE administered in either single or divided doses is recommended.

    Dosage in Children: The initial daily dosage should provide approximately 3 mg/kg of body weight (1.5 mg/lb) administered in either single or divided doses. This dose should be reduced to 1-2 mg/kg for maintenance therapy or combination use with other diuretics.

  3. Essential Hypertension

    Usually in combination with other drugs, ALDACTONE is indicated for patients who cannot be treated adequately with other agents or for whom other agents are considered inappropriate. ALDACTONE has mild to moderate antihypertensive activity.

    For adults an initial daily dosage of 50 mg/day to 100 mg/day (in either single or divided doses) of ALDACTONE is recommended. ALDACTONE may also be given with diuretics that act more proximally in the renal tubule or with other antihypertensive agents. Since a stabilized response may not occur before 2 weeks, continue treatment in either single or divided daily doses for that duration of time. Subsequently, adjust dosage in response to patient's needs. Most patients will respond to doses not exceeding 200 mg/day.

  4. Hypokalemia

    ALDACTONE in dosage ranging from 25 mg to 100 mg daily is useful in treating a diuretic induced hypokalemia, when oral potassium supplements or other potassium sparing regimens are inappropriate. See also Table 2 for a summary of dosage recommendations.
Table 2. ALDACTONE Dosage*
*
Maintenance dosage should be individually determined, and may be lower than the recommended initial dose.
    In Single or Divided Daily Doses
CONDITION TYPE OF TEST INITIAL DOSAGE MAXIMUM DOSAGE
Primary Hyperaldosteronism
  Long Test:

400 mg/day x
3-4 weeks

-
  Short Test: 400 mg/day x
4 days
-
  In Preparation for Surgery: 100‑400 mg/day 400 mg/day
Edematous Disorders:

Congestive Heart Failure

- 100 mg/day 200 mg/day
Cirrhosis Urinary:
Na+ / K+ ratio >1
Na+ / K+ ratio <1

100 mg/day
200-400 mg/day

100 mg/day
400 mg/day
Nephrotic Syndrome - 100 mg/day 200 mg/day
 
Essential Hypertension - 50-100 mg/day 200 mg/day
Hypokalemia - 25-100 mg/day 100 mg/day

Overdosage

Symptoms:  There have been no reports of fatal overdose in man (except indirectly through hyperkalemia).  Nausea and vomiting occurs, and (much more rarely) drowsiness, dizziness, mental confusion, diarrhea, or a maculopapular or erythematous rash.  These manifestations disappear promptly on discontinuation of medication.  Hyperkalemia may be exacerbated.

Treatment:  No specific antidote.  No persistent toxicity has occurred or is expected.  Inducing vomiting and evacuating the stomach by lavage could be considered. Spironolactone use should be discontinued and potassium intake (including dietary sources) restricted.

For management of a suspected drug overdose, contact your regional Poison Control Centre.

Action And Clinical Pharmacology

Mechanism of Action: ALDACTONE (spironolactone) is a specific pharmacologic antagonist of aldosterone, acting primarily through competitive binding of receptors at the aldosterone‑dependent, sodium‑potassium exchange site in the distal convoluted renal tubule. ALDACTONE causes increased amounts of sodium and water to be excreted, while potassium loss is minimized.

ALDACTONE acts both as a diuretic and as an antihypertensive drug by this mechanism. It may be given alone or with other diuretic agents which act more proximally in the renal tubule.

Pharmacodynamics: Increased levels of the mineralocorticoid, aldosterone, are present in primary and secondary hyperaldosteronism. Edematous states in which secondary aldosteronism is usually involved include congestive heart failure, hepatic cirrhosis, and nephrotic syndrome. By competing with aldosterone for receptor sites, ALDACTONE provides effective therapy for the edema and ascites in those conditions. ALDACTONE counteracts secondary aldosteronism induced by the volume depletion and associated sodium loss caused by diuretic therapy.

ALDACTONE is effective in lowering the systolic and diastolic blood pressure in patients with primary hyperaldosteronism. It is also effective in most cases of essential hypertension, despite the fact that aldosterone secretion may be within normal limits in benign essential hypertension.

Through its action in antagonizing the effect of aldosterone, ALDACTONE inhibits the exchange of sodium for potassium in the distal renal tubule and helps to prevent potassium loss.

ALDACTONE has not been demonstrated to elevate serum uric acid, to precipitate gout, or to alter carbohydrate metabolism.

Pharmacokinetics: Spironolactone is rapidly and extensively metabolized to a number of metabolites including canrenone and the sulfur-containing 7-thiomethylspirolactone, both of which are pharmacologically active. Approximately 25 to 30% of the dose administered is converted to canrenone, which attains peak serum levels 2‑4 hours after single oral administration of spironolactone. In the dose range of 25 mg to 200 mg, an approximately linear relationship exists between a single dose of spironolactone and plasma levels of canrenone.

Plasma concentrations of canrenone decline in two distinct phases, the first phase lasting from 3 to 12 hours, being more rapid than the second phase lasting from 12 to 96 hours. Canrenone clearance data, following multiple doses of spironolactone, indicate that accumulation of canrenone in the body with 100 mg once a day would be lower than with 25 mg four times a day. Both spironolactone and canrenone are more than 90‑percent bound to plasma proteins. The metabolites of spironolactone are excreted both in the urine (32‑53%), and through biliary excretion in the feces (14‑36%).

Table 3. Summary of ALDACTONE’s Pharmacokinetic Parameters in Healthy Volunteers Administered 100 mg daily for 15 days

Mean Cmax (ng/mL)

Mean Tmax (h)

Mean Post-Steady State

t½ (h)

Accumulation Factor:

AUC0-24 h, Day 15 / AUC0-24 h, Day 1

7-α-(thiomethyl) spirolactone (TMS)

391

3.2

13.8

1.25

6-Ǝ-hydroxy-7- Ɐ- (thiomethyl) spirolactone (HTMS)

125

5.1

15.0

1.50

Canrenone (C)

181

4.3

16.5

1.41

Spironolactone

80

2.6

~1.4 (t½Ǝ)

1.30

Special Populations

Hepatic Insufficiency

No pharmacokinetic studies have been performed with spironolactone in patients with hepatic insufficiency. Caution is advised in patients with hepatic impairment (see WARNINGS AND PRECAUTIONS – Hepatic/biliary/pancreatic section).

Renal Insufficiency

No pharmacokinetic studies have been performed with spironolactone in patients with renal insufficiency. Aldactone is contraindicated in patients with anuria, acute renal insufficiency or with severe impairment of renal function (GFR < 30 mL/Min/1.73 m2) (see CONTRAINDICATIONS).

Elderly

No pharmacokinetic studies have been performed with spironolactone in the elderly population. Caution is advised in patients with hepatic and/or renal impairment (see CONTRAINDICATIONS and WARNINGS AND PRECAUTIONS – Hepatic/biliary/pancreatic section).

Pediatrics

No pharmacokinetic studies have been performed with spironolactone in the pediatric population. Therefore, safety and effectiveness in pediatric patients have not been established.

Storage And Stability

Store at 15 to 25°C

Dosage Forms, Composition And Packaging

ALDACTONE 25 mg:
Each light yellow, round, biconvex, film-coated tablet, debossed  “ALDACTONE” and “25” on one face and “SEARLE” and “1001” on the other face and with peppermint odour contains Spironolactone 25 mg.

Non‑medicinal ingredients include:  Calcium sulfate, corn starch, magnesium stearate, peppermint flavouring, povidone, hypromellose, polyethylene glycol 400, carnauba wax, stearic acid, and opaspray M-1-2042.

Available in bottles of 100 tablets.

ALDACTONE 100 mg:
Each peach, round, biconvex, scored, film-coated tablet, debossed “ALDACTONE” and “100” on one face and “SEARLE” and “1031” on the other (scored) face and with peppermint odour contains Spironolactone 100 mg.

Non‑medicinal ingredients include: Calcium sulfate, corn starch, magnesium stearate, peppermint flavouring, povidone, hypromellose, polyethylene glycol 400, carnauba wax, stearic acid, and opaspray M-1-2668.

Available in bottles of 100 tablets.

 

Control #: 178267
July 23, 2015

What's New

27 August 2018

PfizerMeds app is designed to support your patients...

Contact Pfizer Medical Information

Report an Adverse Event
1 866 723-7111